Publications by authors named "Kenji Urakabe"
Article Synopsis
- - Cholangiocarcinoma (CCA) is a hard-to-diagnose cancer with limited treatment options, necessitating new targeted therapies; higher leukotriene levels in bile compared to serum were observed, alongside increased expression of the CysLT receptor in CCA tissue.
- - In laboratory tests, leukotriene D4, which activates the CysLT receptor, was found to promote cancer cell growth by triggering important signaling pathways (AKT and ERK1/2 phosphorylation).
- - The use of two existing anti-allergic drugs, zileuton and montelukast, inhibited cancer cell growth and movement, and their combined use further strengthened these effects, indicating potential for repurposing these drugs to treat CCA
A female patient in her 50s who underwent chemotherapy for left primary breast cancer presented with cancerous pleurisy and disseminated intravascular coagulation. Esophagogastroduodenoscopy and liver biopsy revealed gastric and liver cancer. Distinguishing between primary and metastatic cancer by pathological findings is difficult using hematoxylin and eosin staining.
View Article and Find Full Text PDFBackground And Aims: Although long-term stent placement using endoscopic transpapillary gallbladder drainage (ETGBD) and EUS-guided gallbladder drainage (EUS-GBD) reportedly reduces cholecystitis recurrence, comparative evidence of their safety and efficacy is scarce. This study aimed to examine and compare the long-term utility of EUS-GBD versus that of ETGBD in poor surgical candidates.
Methods: A total of 379 high-risk surgical patients with acute calculous cholecystitis met the eligibility criteria for enrollment in this study.
A female patient in her 60s, treated with oral corticosteroids for scleroderma diagnosed 11 years ago, visited our hospital complaining of a persistent fever and liver dysfunction. She was treated with antibiotics, but her fever continued. Abdominal ultrasonography revealed multiple hypoechoic splenic masses.
View Article and Find Full Text PDFAim: We retrospectively investigated patients with administration of nucleos(t)ide analogs (NAs) for prevention of or against hepatitis B virus (HBV) reactivation, and their clinical outcomes after cessation of the NA.
Methods: We enrolled 180 patients who were positive for HBsAg when they started immunosuppressive therapy or chemotherapy and an NA was administered to prevent HBV reactivation (HBV carrier group), and 82 patients with resolved HBV infection who started administration of an NA after HBV reactivation (de novo HBV group). Cessation of the NA depended on each physician's judgment without definite criteria.